Clinicopathologic features of agranulocytosis in the setting of levamisole-tainted cocaine

American Journal of Clinical Pathology

Volumn 133, Issue 3, 2010, Pages 466-472

  Czuchlewski, David R ^a   Brackney, Monica ^b   Ewers, Christina ^b   Manna, Jonaki ^c   Fekrazad, M Houman ^a   Martinez, Afton ^b   Nolte, Kurt B ^a   Hjelle, Brian ^a   Rabinowitz, Ian ^a   Curtis, Brian R ^d   McFarland, Janice G ^d   Baumbach, Joan ^b   Foucar, Kathryn ^a  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b NEW MEXICO DEPARTMENT OF HEALTH   (United States)

^c VANCOUVER ISLAND HEALTH AUTHORITY   (Canada)

^d BLOOD RESEARCH INSTITUTE   (United States)

Author keywords

Agranulocytosis; Cocaine; Levamisole

Indexed keywords

COCAINE; GRANULOCYTE ANTIBODY; LEVAMISOLE; AUTOANTIBODY;

ADULT; AGED; AGRANULOCYTOSIS; ARTICLE; BONE MARROW CELL; CLINICAL ARTICLE; CLINICAL FEATURE; COCAINE DEPENDENCE; CONTROLLED STUDY; FEMALE; HUMAN; LABORATORY TEST; LYMPHOCYTE; MALE; MEGAKARYOCYTE; PRIORITY JOURNAL; TOXICITY TESTING; CHEMICALLY INDUCED DISORDER; DRUG CONTAMINATION; HYPERPLASIA; IMMUNOLOGY; MASS SPECTROMETRY; MIDDLE AGED; NEUTROPHIL; PATHOLOGY; PLASMA CELL;

ADULT; AGED; AGRANULOCYTOSIS; AUTOANTIBODIES; COCAINE; DRUG CONTAMINATION; FEMALE; HUMANS; HYPERPLASIA; LEVAMISOLE; MALE; MASS SPECTROMETRY; MIDDLE AGED; NEUTROPHILS; PLASMA CELLS;

EID: 77949385200     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/AJCPOPQNBP5THKP1     Document Type: Article

References (25)

1. Kaplan B, Cardarelli C, Pinnell SR. Levamisole and agranulocytosis. Cutis. 1979;24:429-430.
2. Amery WK, Bruynseels JP. Levamisole, the story and the lessons. Int J Immunopharmacol. 1992;14:481-486.
3. Conley BA, Kaplan RS, Arbuck SG. National Cancer Institute Clinical Trials Program in Colorectal Cancer. Cancer Chemother Pharmacol. 1998;42(suppl):S75-S79.
4. Dahl O, Fluge Ø, Carlsen E, et al. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. Acta Oncol. 2009;48:368-376.
5. Gerwert S, Failing K, Bauer C. Husbandry management, worm control practices and gastro-intestinal parasite infections of sows in pig-breeding farms in Münsterland, Germany. Dtsch Tierarztl Wochenschr. 2004;111:398-403.
6. Howell SB, Burke JM, Miller JE, et al. Prevalence of anthelmintic resistance on sheep and goat farms in the southeastern United States. J Am Vet Med Assoc. 2008;233:1913-1919.
7. Rosenthal M, Breysse Y, Dixon AS, et al. Levamisole and agranulocytosis [letter]. Lancet. 1977;1:904-905.
8. Amery WK, Butterworth BS. The dosage regimen of levamisole in cancer: is it related to efficacy and safety? Int J Immunopharmacol. 1983;5:1-9.
9. Teerenhovi L, Heinonen E, Gröhn P, et al. High frequency of agranulocytosis in breast-cancer patients treated with levamisole [letter]. Lancet. 1978;2:151-152.
10. Fucci N. Unusual adulterants in cocaine seized on Italian clandestine market [letter]. Forensic Sci Int. 2007;172:e1. doi:10.1016/j.forsciint.2007.05. 021. (Pubitemid 47364762)
11. Valentino AMM, Fuentecilla K. Levamisole: an analytical profile. Microgram J. 2005;3:134-137. http://www.justice. gov/dea/programs/forensicsci/ microgram/journal-v3-num34/ journal-v3-num34-pg3.html. Accessed July 19, 2009.
12. Casale JF, Corbeil EM, Hays PA. Identification of levamisole impurities found in illicit cocaine exhibits. Microgram J. 2008;6. http://www.justice.gov/ dea/programs/forensicsci/ microgram/journal-v6-num34/pg3.html. Accessed July 19, 2009.
13. Zhu NY, Legatt DF, Turner AR. Agranulocytosis after consumption of cocaine adulterated with levamisole. Ann Intern Med. 2009;150:287-289.
14. Davoren A, Saving K, McFarland JG, et al. Neonatal neutropenia and bacterial sepsis associated with placental transfer of maternal neutrophil-specific autoantibodies. Transfusion. 2004;44:1041-1046. (Pubitemid 38823811)
15. Curtis BR, Reno CK, Aster RH. Neonatal alloimmune neutropenia attributed to maternal immunoglobulin G antibodies against the neutrophil alloantigen HNA-1c (SH): a report of five cases. Transfusion. 2005;45:1308-1313.
16. Symoens J, Veys E, Mielants M, et al. Adverse reactions to levamisole. Cancer Treat Rep. 1978;62:1721-1730.
17. Drew SI, Carter BM. Granulocytotoxic autoantibodies in HLA-B27 neutropenic patients. Transplantation. 1979;27:436-437.
18. Chung WH, Hung SI, Chen YT. Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol. 2007;7:317-323. (Pubitemid 47052019)
19. Drew SI, Carter BM, Nathanson DS, et al. Levamisole-associated neutropenia and autoimmune granulocytotoxins. Ann Rheum Dis. 1980;39:59-63.
20. Rosenthal M. Granulocytotoxic antibodies in levamisole-induced agranulocytosis [in German]. Klin Wochenschr. 1982;60:1297-1302.
21. Vanholder R, Van Hove W. Recurrent agranulocytosis after levamisole [letter]. Lancet. 1977;1:100.
22. Vogel CL, Silverman MA, Mansell PW, et al. Mechanisms of levamisole-induced granulocytopenia in breast cancer patients. Am J Hematol. 1980;9:171-183. (Pubitemid 11199274)
23. Thompson JS, Herbick JM, Klassen LW, et al. Studies on levamisole-induced agranulocytosis. Blood. 1980;56:388-396.
24. Peikert T, Finkielman JD, Hummel AM, et al. Functional characterization of antineutrophil cytoplasmic antibodies in patients with cocaine-induced midline destructive lesions. Arthritis Rheum. 2008;58:1546-1551. (Pubitemid 351705946)
25. Kouassi E, Caillé G, Léry L, et al. Novel assay and pharmacokinetics of levamisole and p-hydroxylevamisole in human plasma and urine. Biopharm Drug Dispos. 1986;7:71-89. (Pubitemid 16155186)